Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
November 06, 2018 07:00 ET
|
Ritter Pharmaceuticals, Inc.
Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019...
Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance
May 22, 2018 08:30 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split
March 22, 2018 11:35 ET
|
Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that...
Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
March 19, 2018 06:35 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, March 19, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate...
Chapman Global Medical Center Achieves National Accreditation and Recognition for Metabolic and Bariatric Surgery
March 08, 2018 05:00 ET
|
KPC Healthcare Inc.
Orange County, CA, March 08, 2018 (GLOBE NEWSWIRE) -- Patients seeking surgical treatment for severe obesity and its related conditions have a high-quality choice for receiving treatment. Chapman...
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial
January 29, 2018 09:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the human gut...
MicroBiome Therapeutics Completes Series B Financing and Prepares to Launch First Microbiome Modulator Product
November 01, 2017 07:00 ET
|
MicroBiome Therapeutics, LLC
NEW ORLEANS, La., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MicroBiome Therapeutics, LLC (MBT), a leading company applying the science of the gastrointestinal (GI) microbiome to promote health and wellness,...
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
October 31, 2017 06:45 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering
September 29, 2017 08:00 ET
|
Ritter Pharmaceuticals
Los Angeles, California, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Clinical "CSI" for Your Body
February 11, 2008 10:30 ET
|
LaValle Metabolic Institute
CINCINNATI, OH--(Marketwire - February 11, 2008) - Don't beat yourself up if your resolution to
lose a few pounds fails. It may not be your fault.
Metabolic expert Jim LaValle says if you've always...